TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21620926

Group type: EXPERIMENTAL
Intervention: MOD restored with resin composite
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MOD plus extensive endodontic access, GIC core and resin composite
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unrestored MOD cavity
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unrestored MOD cavity plus endodontic access through the occlusal floor
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unrestored MOD plus endodontic access with axial walls removed
Number of subjects: 80
Study: 18363581

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (150 mg, 3 times daily for 1 week after each blood donation)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 16492219

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12671696

Group type: EXPERIMENTAL
Intervention: Active lozenges (PTA) containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg, four times daily during radiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo lozenges, four times daily during radiotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Active lozenges (PTA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 65
Study: 10880416

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 66
Study: 8938220

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cyclophosphamide and methotrexate followed by concomitant 5-fluorouracil and irradiation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 38
Study: 1534876

Group type: EXPERIMENTAL
Intervention: Sufentanil N2O/O2 with 0.25% isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfentanil N2O/O2 with 0.25% isoflurane
Number of subjects: 0
Study: 3694302

Group type: EXPERIMENTAL
Intervention: Gauze dressing
Number of subjects: 301

Group type: COMPARATOR
Intervention: Uniflex transparent plastic dressing
Number of subjects: 301

Group type: COMPARATOR
Intervention: Tegaderm transparent plastic dressing
Number of subjects: 301
Study: 30574609

Group type: EXPERIMENTAL
Intervention: Intensive oral care programme (IOCP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.03% triclosan mouthrinse
Number of subjects: 48
Study: 26000622

Group type: EXPERIMENTAL
Intervention: Active music therapy (MT) in addition to speech language therapy (SLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Speech language therapy (SLT) alone
Number of subjects: 20
Study: 25151488

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily during radiation therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23870627

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 274
Study: 21389934

Group type: EXPERIMENTAL
Intervention: Levetiracetam (keppra) as first monotherapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Levetiracetam (keppra) as second or third monotherapy
Number of subjects: 143
Study: 17803835

Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy (BEP) in 16 weekly individual sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 20
Study: 19652253

Group type: EXPERIMENTAL
Intervention: Glidewire
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZipWire
Number of subjects: 100

Group type: COMPARATOR
Intervention: HiWire
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All guidewires
Number of subjects: 100
Study: 15151349

Group type: EXPERIMENTAL
Intervention: Intervention groups
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol-specific programs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multicomponent programs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Educational-based interventions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Office-based interventions
Number of subjects: 12
Study: 11890650

Group type: EXPERIMENTAL
Intervention: Etanercept (TNF inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab (TNF inhibitor)
Number of subjects: 0
Study: 9596436

Group type: EXPERIMENTAL
Intervention: Mechanical CPR (TCPR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human/manual CPR (HCPR)
Number of subjects: 20
Study: 7930736

Group type: EXPERIMENTAL
Intervention: Folinic acid with trimethoprim-sulfamethoxazole
Number of subjects: 92

Group type: COMPARATOR
Intervention: Matching placebo with trimethoprim-sulfamethoxazole
Number of subjects: 92
Study: 3283292

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg daily in three divided doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31644512

Group type: EXPERIMENTAL
Intervention: Spritztube tracheal cannula
Number of subjects: 334

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Supreme (LMA-S)
Number of subjects: 334
Study: 27920262

Group type: EXPERIMENTAL
Intervention: Home exercise programme filmed on an electronic tablet with automated reminders (n=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard paper-based home exercise programme (n=32)
Number of subjects: 62
Study: 26159792

Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) 1000 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 24326529

Group type: EXPERIMENTAL
Intervention: Gynocular
Number of subjects: 540

Group type: COMPARATOR
Intervention: Stationary colposcope
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 540

Group type: COMPARATOR
Intervention: Liquid-based cytology
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 540
Study: 22045779

Group type: EXPERIMENTAL
Intervention: Irrevocable ostracism by an outgroup (based on nationality)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrevocable ostracism by an outgroup (based on personal preferences)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ostracism by the ingroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ostracism based on being 'too good' for the group
Number of subjects: 0
Study: 19074207

Group type: EXPERIMENTAL
Intervention: Green tea catechin beverage (625 mg of catechins with 39 mg caffeine)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control beverage (39 mg caffeine, no catechins)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Green tea catechin beverage
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 132
Study: 18024494

Group type: EXPERIMENTAL
Intervention: Atrial septal pacing
Number of subjects: 43

Group type: COMPARATOR
Intervention: High right atrial pacing
Number of subjects: 43
Study: 14971832

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 2750
Study: 11564123

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,000 mg/day
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Levetiracetam 2,000 mg/day
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3,000 mg/day
Number of subjects: 904

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 904
Study: 9040320

Group type: EXPERIMENTAL
Intervention: 5 micrograms of the new hepatitis B vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 micrograms of the new hepatitis B vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 micrograms of the new hepatitis B vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 micrograms of the new hepatitis B vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 micrograms of the new hepatitis B vaccine (single dose)
Number of subjects: 100
Study: 8176527

Group type: EXPERIMENTAL
Intervention: Warm water compress
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Warm moist tea bag compress
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Expressed milk massaged into the nipple and areola and air dried
Number of subjects: 73

Group type: COMPARATOR
Intervention: Instruction only (control group)
Number of subjects: 73
Study: 2976406

Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg/day initial dose for 4 weeks, mean dose 30.7 mg/day at end of study)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etretinate (initial dose not specified, mean dose 33.4 mg/day at end of study)
Number of subjects: 20
Study: 28815689

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study: 27264224

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneous injections
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo subcutaneous injections
Number of subjects: 968
Study: 25016509

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study: 22948196

Group type: EXPERIMENTAL
Intervention: Oral intake of 2 L of 0.9% saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous infusion of 2 L of 0.9% saline
Number of subjects: 10
Study: 21191426

Group type: EXPERIMENTAL
Intervention: Combination niacin extended-release + simvastatin (NER/S)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 137
Study: 18762754

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microg kg(‐1) as bolus before induction and 0.2 microg kg(‐1) h(‐1) by infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) as bolus before induction and 0.5 microg kg(‐1) h(‐1) by infusion
Number of subjects: 50
Study: 15915020

Group type: EXPERIMENTAL
Intervention: 0.625 mg intravenous droperidol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1.25 mg intravenous droperidol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol and saline
Number of subjects: 120
Study: 12350439

Group type: EXPERIMENTAL
Intervention: Mobile phone operating
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mobile phone turned off
Number of subjects: 24
Study: 9856967

Group type: EXPERIMENTAL
Intervention: 0.4 mg moxonidine
Number of subjects: 25
Study: 11785199

Group type: EXPERIMENTAL
Intervention: Alugastrin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gastrin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Wikalina
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 2744779

Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg slow release twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg twice daily)
Number of subjects: 15
Study: 984352

Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) given orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) given intramuscularly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) organic preparation (Nembutal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) aqueous solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) injected by doctors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) injected by nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 29472259

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 66
Study: 26727407

Group type: EXPERIMENTAL
Intervention: Full Personalized Normative Feedback (PNF)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Partial Personalized Social Comparison Feedback (PSCF)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 623
Study: 25092211

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of ropivacaine (2 mL/hour of 0.375% ropivacaine after initial 10 mL of 0.75% ropivacaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent epidural ropivacaine (10 mL of 0.75% ropivacaine followed by 10 mL of 0.2% ropivacaine every 6 hours)
Number of subjects: 0
Study: 22075651

Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (PIT), 12 weekly sessions
Number of subjects: 211

Group type: COMPARATOR
Intervention: Enhanced medical care (EMC), 3 sessions
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (PIT)
Number of subjects: 211
Study: 20977840

Group type: EXPERIMENTAL
Intervention: Ultra-micronized BYHWD (5 g, twice a day) for 12 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Traditional BYHWD (15 g, twice a day) for 12 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 251
Study: 18985152

Group type: EXPERIMENTAL
Intervention: Virtual faces (avatars)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Natural human faces
Number of subjects: 32
Study: 15804330

Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis using short ECG recordings
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis in diabetes group
Number of subjects: 48
Study: 12576829

Group type: EXPERIMENTAL
Intervention: Hydrophilic coated LoFric catheter
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard plastic catheter
Number of subjects: 62
Study: 11301846

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin plus etoposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin plus vinorelbine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin plus mitomycin and ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine regimens
Number of subjects: 0
Study: 9112100

Group type: EXPERIMENTAL
Intervention: Interactive videodisc programs designed to reduce HIV/STD risk behaviors
Number of subjects: 827
Study: 8466735

Group type: EXPERIMENTAL
Intervention: Isradipine SRO at 2.5 mg/day (increased to 5 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Enalapril at 10 mg/day (increased to 20 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Number of subjects: 52
Study: 3553316

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 31356456

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study: 30111378

Group type: EXPERIMENTAL
Intervention: Immediate prophylactic application of incisional Negative-pressure Wound Therapy (iNPWT) following ILND
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative treatment
Number of subjects: 0
Study: 27457478

Group type: EXPERIMENTAL
Intervention: Multi-Family Group (MFG) intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Active SCI education control (SCIEC)
Number of subjects: 32
Study: 25444821

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PCV-9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22883166

Group type: EXPERIMENTAL
Intervention: Placebo with 20 mmHg cuff pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo with 40 mmHg cuff pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo with 60 mmHg cuff pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin C with 60 mmHg cuff pressure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control arm (no cuff pressure)
Number of subjects: 12
Study: 20828877

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 122
Study: 18821638

Group type: EXPERIMENTAL
Intervention: Behavioral interventions for arthritis
Number of subjects: 25
Study: 15956038

Group type: EXPERIMENTAL
Intervention: CMFEV (CMF plus epirubicin and vincristine)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 211
Study: 11226117

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 36
Study: 9776796

Group type: EXPERIMENTAL
Intervention: Dietary recall method
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Training effect during the study
Number of subjects: 7
Study: 7830214

Group type: EXPERIMENTAL
Intervention: Enhanced child involvement condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment condition
Number of subjects: 0
Study: 2893533

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1441970

Group type: EXPERIMENTAL
Intervention: Partial phenolization of the germinal matrix
Number of subjects: 0
Study: 21610

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 494

Group type: COMPARATOR
Intervention: Clindamycin hydrochloride
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 31170542

Group type: EXPERIMENTAL
Intervention: Direct Challenge (DC)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Penicillin Skin Testing (PST)
Number of subjects: 159
Study: 28203730

Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Extended head position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Flexed head position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rotated head position
Number of subjects: 51
Study: 25523633

Group type: EXPERIMENTAL
Intervention: Anagliptin (100mg twice daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sitagliptin (100mg once daily)
Number of subjects: 180
Study: 24554938

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 19573436

Group type: EXPERIMENTAL
Intervention: High amino acid group (HP): 2.4 g/(kg.d) of amino acid IV within 24 hours after birth
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High amino acid group (HP)
Number of subjects: 96
Study: 16708511

Group type: EXPERIMENTAL
Intervention: Multifaceted environmental and educational intervention (dust mite covers, professional house cleaning, roach bait and trays)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Delayed intervention (no immediate intervention)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 410
Study: 16159869

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg body weight for 6 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 11579299

Group type: EXPERIMENTAL
Intervention: Induction therapy with ATG
Number of subjects: 309

Group type: COMPARATOR
Intervention: Immediate tacrolimus-based triple therapy
Number of subjects: 309
Study: 9585718

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day for 7 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nortriptyline (3 weeks treatment)
Number of subjects: 27
Study: 8142644

Group type: EXPERIMENTAL
Intervention: Hu‐M195 at 0.5, 1.0, 3.0, and 10.0 mg/m2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hu‐M195 at 3 mg/m2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hu‐M195
Number of subjects: 13
Study: 3344597

Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg (i.m.)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg (i.m.)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Meperidine 80 mg (i.m.)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: All treatment groups (Butorphanol 4 mg, Butorphanol 2 mg, Meperidine 80 mg)
Number of subjects: 203
Study: 28439928

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation (UI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Needle irrigation (NI)
Number of subjects: 50
Study: 28982656

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention addressing the obesogenic environment
Number of subjects: 736

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 736
Study: 25396353

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0
Study: 23494582

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Drain in situ
Number of subjects: 160
Study: 21266302

Group type: EXPERIMENTAL
Intervention: Collaborative Behavioral Management (CBM)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Standard Parole
Number of subjects: 431
Study: 19825186

Group type: EXPERIMENTAL
Intervention: Surgical CVP reduction by clamping of the IVC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anaesthesiological CVP without infrahepatic IVC clamping reduction
Number of subjects: 0